window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : February 10, 2026

  • News
  • About Us
Contact Us

Artificial Intelligence

  • Artificial Intelligence,Biotech,Drug Development,Mergers & Acquisitions,Technology and platforms

    CombinAbleAI to be acquired by insitro to expand AI drug discovery platform

    AI therapeutics company, insitro, has agreed to acquire CombinAbleAI in [...]

    January 14, 2026
  • Artificial Intelligence,Digital Health,Healthcare leadership,Movers & Shakers,Pharmaceuticals and therapeutics

    CluePoints names Sinead Godkin CPO to scale global workforce

    CluePoints has appointed Sinead Godkin as chief people officer, strengthening [...]

    January 14, 2026
  • Artificial Intelligence,Data Management,Pharmaceuticals and therapeutics,Technology and platforms

    Gap emerges between agentic AI ambition and real-world use in pharma, report finds

    A growing gap has emerged between how life sciences and [...]

    January 13, 2026
  • Artificial Intelligence,Biotech,Drug Development,Pharmaceuticals and therapeutics,Precision medicine,Research & Development,Technology and platforms

    CytoReason unveils LINA, AI agent accelerated by NVIDIA for pharma R&D

    CytoReason has unveiled LINA, an AI agent designed to support [...]

    January 13, 2026
  • Artificial Intelligence,Drug Development,European biotech,Partnerships & Funding,Technology and platforms

    FluoSphera raises €1.23 million to scale human-based preclinical testing platform

    Swiss biotech startup FluoSphera has raised €1.23 million (CHF 1.15 [...]

    January 12, 2026
  • Artificial Intelligence,Clinical Development,Clinical Trials,Data Management,Oncology,Research & Development

    Breast cancer tops list of most-studied diseases for fifth consecutive year, Phesi analysis finds

    Breast cancer remained the world’s most studied disease for the [...]

    January 9, 2026
  • Artificial Intelligence,Clinical Development,Clinical Trials,Data Management,Technology and platforms

    Medable launches AI agent to automate trial master file workflows

    Medable has launched a new artificial intelligence-powered agent designed to [...]

    January 7, 2026
  • Artificial Intelligence,Clinical Development,Clinical Trials,Data Management,Digital Health,Medical devices,Technology and platforms

    12th Day of Christmas: Ledger Run and AcuityMD predict AI will drive operational change across clinical trials and MedTech in 2026

    On the 12th Day of Christmas in Discover Pharma’s industry [...]

    January 5, 2026
  • Artificial Intelligence,Clinical Development,Clinical Trials,Digital Health,Regulatory Affairs,Technology and platforms

    11th Day of Christmas: Medable predicts agentic AI will reshape clinical trials and regulation in 2026

    On the 11th Day of Christmas in Discover Pharma’s industry [...]

    December 31, 2025
  • Artificial Intelligence,Clinical Development,Clinical studies,Clinical Trials,Patient Centricity

    Like the ten leaping Lords, PHARMASEAL takes a leap towards smarter growth in 2026

    With the lords a-leaping, the industry is set to spring [...]

    December 30, 2025
Previous123Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Quest Diagnostics launches flow cytometry MRD blood test for myeloma to support ultrasensitive monitoring
    Categories: Diagnostics, Hematology, Oncology, Real world evidence
  • Levicept appoints James Sandy as chief development officer to advance LEVI-04 for osteoarthritis
    Categories: Biologics & Biosimilars, Clinical Development, Clinical Trials, Drug Development, Movers & Shakers, Orthapaedics, Rare Diseases
  • Cereno Scientific completes expanded access program milestone for CS1 in pulmonary arterial hypertension
    Categories: Cardiovascular diseases, Clinical Trials, Rare Diseases, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top